
David Wainer
PersonHeard in 3 episodes across 3 shows since Aug 2026
David Wainer is a columnist for The Wall Street Journal’s Heard on the Street section. He writes about Wall Street and companies in sectors including healthcare, food and travel.
Episodes
First heard
Guest appearances
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 1 |
| Sep 2026 | 1 |
| Oct 2026 | 1 |
| Nov 2026 | 0 |
Email alert
Email me when David Wainer comes up on a podcast
One email a week at most, with the new episodes that mention David Wainer. Free, no account needed, unsubscribe in one click.
What David Wainer has said on podcasts
18 statements
Trump’s agreements ended drug tariffs and established drug-pricing regulation.
“Eventually, in late 2025, Trump signs these agreements, starting with Albert Bourla, the CEO of Pfizer, basically declaring the whole thing over. Tariffs are off. Drug pricing regulation is agreed upon.”
Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?Listen at 3:18
Large pharmaceutical companies are better at acquisitions than internal innovation.
“They're no longer really good at innovating. They're really good at acquiring companies.”
Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?Listen at 4:06
Capital is rotating from AI toward healthcare investments.
“healthcare which was kind of back here partly because of policy but also partly because ai was driving all the investment now it's sort of like money is rotating back”
Open the episode · A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last?Listen at 5:28
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
3 episodes featuring David Wainer, newest first
- Oct 13, 2026
Oura’s stalled IPO exposes the limits of wearable hypeThe Journal.Oct 13, 2026Guest - Sep 13, 2026
Biotech’s rally tests the promise of cancer breakthroughsWSJ's Take On the WeekSep 13, 2026Guest - Aug 24, 2026
Trump widens pressure campaign as markets parse Iran’s oil flowsWSJ What’s NewsAug 24, 2026Guest